Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 56 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NWnlVnVyTnWwY4Tpc44hSXO|YYm= Ml;LNE42NzFxMj61JO69VQ>? Mlz6N{Bp MkW3doVlfWOnczD0bIUh[mG|YXygR2IhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYDtSXlsOjZyOUe4O|M>
T24 BC  MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVewMlUwOS9{LkWg{txO NXXMT3ZXOjRiaB?= MkLG[Y5p[W6lZYOgd49z[W[nbnniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliZHXjdoVie2V? MWmyOlA6Pzh5Mx?=
T24 BC  M4ruNGFxd3C2b4Ppd{BCe3O|YYm= MoPsNk42KM7:TR?= NULlUVJUOjRiaB?= NIPx[YZ{\W6|aYTpfoV{KEKFIHPlcIx{KHSxIIPvdoFn\W6rYj3pcoR2[2WmIHHwc5B1d3SrY9Mg NVzkUpZPOjZyOUe4O|M>
HepG2 MWDGeY5kfGmxbjDBd5NigQ>? NEDqdmgzOMLizszN NIPMTmYzPMLiaB?= M2TrbJBzd2S3Y3XzJIFvKGmwdHXud4Uh[3m2b4DsZZNucWNidnHjeY9tcXqjdHnvckBkd3K{ZYPwc45lcW6pIITvJIEhdm:2YXLs[UBlcWyjdHH0bY9vKG:oIITo[UBGWiClaYP0[ZJvew>? M4PwW|I2QTN2MkOy
U-87 MG  NXLUPVl1TnWwY4Tpc44hSXO|YYm= MkjXNlDDqM7:TR?= NYnLNXh3OjUEoHi= NWnRU3l7cW6lcnXhd4V{KGSxdXLs[U1u\W2kcnHu[UBjd3WwZDDzeJJ2[3S3cnXz NYfpcHU6OjV7M{SyN|I>
HepG2 MlP3SpVv[3Srb36gRZN{[Xl? MU[yNOKh|ryP M2mzO|YwOjRiaB?= NGDyb2FqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? NHr3bIIzPTl|NEKzNi=>
U-87 MG  M4ToW2Z2dmO2aX;uJGF{e2G7 NUTPbnRkOjEEoN88US=> NY\lWJA5Pi9{NDDo NFnKWJBqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? NH73[W8zPTl|NEKzNi=>
HepG2 NGjrNZlHfW6ldHnvckBCe3OjeR?= NWDhPJNnOjEEoN88US=> NH7qRWM3NzJ2IHi= MXrk[YNz\WG|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=> NXP3N21FOjV7M{SyN|I>
U-87 MG  M3\BRmZ2dmO2aX;uJGF{e2G7 MkHYNlDDqM7:TR?= NF7FOmE3NzJ2IHi= NH7nWpFqdmO{ZXHz[ZMhfGinIHH1eI9xcGGpaXOg[ox2gCBiYYSgOkBpKHeqaXzlJIlvcGmkaYTzJJRpcXNiZnz1fEBifCB{NHi= NVP5VVU{OjV7M{SyN|I>
HepG2 NUL3NVllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO4VXQzOC92MDFOwG0> NWDZdFRjOjRxNEigbC=> MonIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NH\JRo0zPTl|NEKzNi=>
U-87 MG  M{PvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHQZ4kzOC92MDFOwG0> NGS3cpYzPC92ODDo M2fwO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MkTDNlU6OzR{M{K=
A549 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrm[2YxNjNvMUCg{txO NEPhfo0zPC95MjDo M4fZZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NF7XVpYzPTZ7N{i5PS=>
H460 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnJe2cxNjNvMUCg{txO Ml;qNlQwPzJiaB?= NVPTZ3dicW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MXuyOVY6Pzh7OR?=
A549 NGTtXXZCeG:ydH;zbZMhSXO|c3H5 NXfKT4F7OS9|IN88US=> NXfBN3plPDhiaB?= M1GyN4lv\HWlZYOgZZBweHSxc3nz NYj0TXF[OjV4OUe4PVk>
H460 NHzKRnNCeG:ydH;zbZMhSXO|c3H5 NFzGOpIyNzNizszN MWG0PEBp NHG4d3RqdmS3Y3XzJIFxd3C2b4Ppdy=> NEP3UlQzPTZ7N{i5PS=>
A549 MY\GeY5kfGmxbjDBd5NigQ>? NHTZWIQ{KM7:TR?= NHPXR285KGh? MUnicI9kc3NiQVvUJIFkfGm4YYTpc44> M1u3bFI2Pjl5OEm5
H460 NV3mRolzTnWwY4Tpc44hSXO|YYm= MUGzJO69VQ>? NELpO4I5KGh? NEDYXYVjdG:la4OgRWtVKGGldHn2ZZRqd25? NYnnem5TOjV4OUe4PVk>
A549 NUW2SmtsTnWwY4Tpc44hSXO|YYm= NVPGVJFnOyEQvF2= NUDsfld4QCCq M4\xVYJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= MlvUNlU3QTd6OUm=
H460 M3W5UWZ2dmO2aX;uJGF{e2G7 MUSzJO69VQ>? NUDEW4pOQCCq MojRZoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ MX6yOVY6Pzh7OR?=
RMG1 NXWyO4NbS2WubDDWbYFjcWyrdImgRZN{[Xl? NXK3WlNJOS1|MDFOwG0> NWf2dYxKPzJiaB?= M{j5[oRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHjuOoUzPTVzOUG0PC=>
RMG2 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{\D[|EuOzBizszN MYW3NkBp M4DJR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NEC3bmgzPTVzOUG0PC=>
KOC7C MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXHmUGRzOS1|MDFOwG0> MnLGO|IhcA>? MWrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1nySlI2PTF7MUS4
HAC2 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYGxMVMxKM7:TR?= NV;nPYhDPzJiaB?= MkLE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2jKflI2PTF7MUS4
RMG2 Ml3VR4VtdCCYaXHibYxqfHliQYPzZZk> NFX1[|AyNTNyIN88US=> MV20PEBp MonT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NUnVW5hXOjV3MUmxOFg>
OVISE MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkDyNU0{OCEQvF2= Mk\QOFghcA>? NYrJTmJx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MnH5NlU2OTlzNEi=
SKOV3 M2nXS2NmdGxiVnnhZoltcXS7IFHzd4F6 NIjSdGsyNTNyIN88US=> NWLuR4I2PDhiaB?= NEX0UIZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYSyOVUyQTF2OB?=
A2780 NE[yO2pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnT0NU0{OCEQvF2= NWX3bYVXPDhiaB?= MmT2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NWGweWxDOjV3MUmxOFg>
RMG1 MnXqRZBweHSxc3nzJGF{e3OjeR?= NF\rbo8{OCEQvF2= MUmyOEBp M3vPcolv\HWlZYOgZZBweHSxc3nz MXiyOVUyQTF2OB?=
RMG2 M3T6ZWFxd3C2b4Ppd{BCe3O|YYm= M{fuOFMxKM7:TR?= MlvnNlQhcA>? MYnpcoR2[2W|IHHwc5B1d3Orcx?= NV7zWpFUOjV3MUmxOFg>
HCC1806 NF7EWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrkVVQxNTFyIN88US=> MV20PEBp NI\zVZRGSzVyPUKuPFTjiIoEsfMAjVAvODdizszN NWrBfIY6OjV{OUO1O|Y>
MDA-MB-231  M2m5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\aRokxNTFyIN88US=> MnXWOFghcA>? NGDQXnRGSzVyPUGuNVPjiIoEsfMAjVAvODdizszN MYWyOVI6OzV5Nh?=
GL-1 NGP6[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rSSVAvOeLCk{GwNQKBkc7:TR?= M{CwPFQ5KGh? MYPJR|UxRTlwOUGg{txO Mo[4NlQ5QDF3MEi=
CLBL-1 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf5S2wxNjIkgKOxNFDjiIoQvF2= NWD0ZYJOPDhiaB?= NHf0RVNKSzVyPUOzMlAh|ryP M37KelI1QDhzNUC4
UL-1 M2nRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlHjiJNzMEFihKnPxE1? MmPPOFghcA>? MlTrTWM2OD15LkCxJO69VQ>? NFTWTYMzPDh6MUWwPC=>
Ema NGXjeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMlHjiJNzMEFihKnPxE1? NVzQbJJMPDhiaB?= M1;5N2lEPTB;NUiuO{DPxE1? MWKyOFg5OTVyOB?=
PANC-1 M3n3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DYRlAuOjVizszN M163NlczKGh? M13sWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4TBO|I1PTF7N{Wx
MIA NY\nNWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqxNYMxNTJ3IN88US=> NEH5N5U4OiCq NXfPPFM{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3W0Z|I1PTF7N{Wx
AsPC-1 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfoeIV3OC1{NTFOwG0> NYfpW4ZYPzJiaB?= NWDaVJUzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXyyOFUyQTd3MR?=
PANC-1 M4r5WWZ2dmO2aX;uJGF{e2G7 M4jvWVAvPSEQvF2= M2\VfVI1KGh? MnnNbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh MkKzNlQ2OTl5NUG=
MIA NXHVdWN{TnWwY4Tpc44hSXO|YYm= M2\SeFAvPSEQvF2= NFqyRoUzPCCq MoL2bY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh NGi1b3czPDVzOUe1NS=>
AsPC-1 M1P4ZWZ2dmO2aX;uJGF{e2G7 M2SwOFAvPSEQvF2= NXPSU5U3OjRiaB?= NVzC[mZXcW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi NULnNHlFOjR3MUm3OVE>
U87MG NXzQR|ZnS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HucFAuOjVizszN M1HrclI1NTl4IHi= MVrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M3rvblI1ODZ3NUKy
SGC7901  NHrO[|lHfW6ldHnvckBCe3OjeR?= MWOwMlc2NzFywrFOwG0> NFjsUlA1QCCq M4fKVIRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=> NGH2cIwzOzlzMkK0Oi=>
MGC803  M2XBXWZ2dmO2aX;uJGF{e2G7 NXLWT3Y6OC55NT:xNOKh|ryP MUG0POKhcA>? NWrLelFP\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh Mk\kNlM6OTJ{NE[=
TykNu MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNTFOwG0> NYXSbllqOjN6N{ewNVI>
TykNuR Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LDVWlEPTB;NT61JO69VQ>? MWCyN|g4PzBzMh?=
M41 NULQPVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJ2Lkeg{txO M{LhXlI{QDd5MEGy
M41R MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2xN2ZKSzVyPUG5Mlgh|ryP NY\oW2l4OjN6N{ewNVI>
OVCAR8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknPTWM2OD1|MT6xJO69VQ>? M3\QOFI{QDd5MEGy
HeyA8 M3fPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ2LkOg{txO MYeyN|g4PzBzMh?=
A2780CP MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYewOGFCUUN3ME23MlYh|ryP NHPadpYzOzh5N{CxNi=>
OVCAR5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\lfllkUUN3ME22Mlch|ryP MXmyN|g4PzBzMh?=
A2780S MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnnS3BKSzVyPUG0MlUh|ryP MmH2NlM5PzdyMUK=
MCAS NGi4cmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\1TWM2OD1zMj61JO69VQ>? Ml3QNlM5PzdyMUK=
NCI-H727 M{\HWWNmdGxiVnnhZoltcXS7IFHzd4F6 MmjSNE0yODBizszN NF24fFEzPC95MjDo NF6xUWdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NHHFVZYzOjR7OUSzOy=>
GOT1 NGHKc4lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWrhVZBMOC1zMECg{txO NX;4[21QOjRxN{KgbC=> Ml;Q[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M2nKZVIzPDl7NEO3
BON1 NFO1XlZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYWwMVExOCEQvF2= MYOyOE84OiCq MWPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M1r4cFIzPDl7NEO3
BON1 MVfBdI9xfG:|aYOgRZN{e2G7 NXz0dnJIOC1zMDFOwG0> M{[3ZVI1KGh? NEjUU|JqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MXOyNlQ6QTR|Nx?=
BON1 M1HSRmZ2dmO2aX;uJGF{e2G7 MoPMO{42NzFyIN88US=> M3S1bFghcA>? NHr0WYxl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhfGinIHHueIku[XCxcITveIlkKHC{b4TlbY5{KEKFTEKgZY5lKEKlbD3YUC=> MVqyNlQ6QTR|Nx?=
Kasumi-1 M1qyVWNmdGxiVnnhZoltcXS7IFHzd4F6 M{OxWlAuOjBizszN NVLT[Vl7OjRxNEigbC=> NX35[ld2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MlHBNlI1ODd{Mki=
HL-60 NELUeFVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2ez[FAuOjBizszN MonVNlQwPDhiaB?= M3PGXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NWHQcVBuOjJ2MEeyNlg>
Kasumi-1 MlK5RZBweHSxc3nzJGF{e3OjeR?= MXGxNEDPxE1? MnPSNlQhcA>? NVjJPZAycW6mdXPld{BieG:ydH;zbZM> M3;qRVIzPDB5MkK4
HL-60 M2\uW2Fxd3C2b4Ppd{BCe3O|YYm= M{LjRlExKM7:TR?= M17VZVI1KGh? NFLHe3JqdmS3Y3XzJIFxd3C2b4Ppdy=> MkTCNlI1ODd{Mki=
Kasumi-1 MY\GeY5kfGmxbjDBd5NigQ>? NXfQfIt6Oi53L{WvNVAh|ryP NV\kdm1FOjRiaB?= MYjk[YNz\WG|ZYOgRYt1KGGwZDDwMWFsfCCuZY\lcJPDqGSxc3Wt[IVx\W6mZX70cJk> MVmyNlQxPzJ{OB?=
HL-60 NWnaW292TnWwY4Tpc44hSXO|YYm= M3fIR|IvPS93L{GwJO69VQ>? MUmyOEBp MmK1[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6 MVGyNlQxPzJ{OB?=
Kasumi-1 MVHGeY5kfGmxbjDBd5NigQ>? M3rDVlIvPS93L{GwJO69VQ>? MU[yOEBp Mn;ZbY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnzuNlI1ODd{Mki=
HL-60 MUTGeY5kfGmxbjDBd5NigQ>? MYiyMlUwPS9zMDFOwG0> NF;ScI0zPCCq Mn[ybY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MU[yNlQxPzJ{OB?=
K562 NWPNPWNKTnWwY4Tpc44hSXO|YYm= NXLmNZd4OjBizszN M1XxdFQ5KGh? M2Kwe4lv\HWlZYOgZZV1d3CqYXf5xsA> MmfVNlI1ODd{Mki=
OCUT1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILHUmsxNjFvMzFOwG0> MoTnOUBl M4flWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWSyNlA6ODJ5MR?=
K1 M2LYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljjNE4yNTNizszN Mnr0OUBl NHPXW3NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1X0OFIzODlyMkex
OCUT1 MWTGeY5kfGmxbjDBd5NigQ>? M4jjNlMh|ryv MWmyOEBp MX3jZZV{\XNiYTDkdoFu[XSrYzDpcoNz\WG|ZTDpckBIOi:PIIDoZZNm MXOyNlA6ODJ5MR?=
CaOV3 MlfNR4VtdCCYaXHibYxqfHliQYPzZZk> M4OxNFEwPS9zMDFOwG0> MXO0PEBp NXvuTZp6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy= MXeyNVc4PTB3NB?=
SKOV3 NV\mPFlWS3m2b4TvfIlkcXS7IFHzd4F6 M{KyS|Uh|ryP NITVbJg1QCCq NF7JVnVmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh NWSzR4NqOjF5N{WwOVQ>
A2780 MoPRR5l1d3SxeHnjbZR6KEG|c3H5 NWDpcphnPSEQvF2= NHX0XG81QCCq MoHJ[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> MnnVNlE4PzVyNUS=
HT-29  MX;DfZRwfG:6aXPpeJkhSXO|YYm= NGj5[XY2KM7:TR?= MmPJOFghcA>? NVvaSlNk\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? NIH2S2QzOTd5NUC1OC=>
A498 NY\IN5hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6wMVQxKM7:TR?= MoH4O|IhcA>? NYH3OIxmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVGyNVY1PDB3MB?=
CAKI-1 NVzJVVBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiwMVQxKM7:TR?= MVq3NkBp NXfGTW1WUUN3MI6xNEDPxE1? NGDuTVQzOTZ2NEC1NC=>
769-P MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fyd|AuPDBizszN MmDtO|IhcA>? MX7JR|UxhjVvMUCg{txO MoPDNlE3PDRyNUC=
786-0 NGTIXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K3dFAuPDBizszN NGKwNlQ4OiCq MWfJR|UxhjVizszN MX2yNVY1PDB3MB?=
786-O NFjlco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILNXmwxNTJyIN88US=> Ml;aO|IhcA>? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXKyNVY1PDB3MB?=
CAKI-1 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WyelAuOjBizszN MVi3NkBp M1X1[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2fDd|IyPjR2MEWw
769-P NITWZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDSWo9QOC1{MDFOwG0> NWHuSHpQPzJiaB?= MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MkG2NlE3PDRyNUC=
A498 NYTRSohGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3RNGd5OC1{MDFOwG0> Mn[2O|IhcA>? M3\3cYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIT2TG4zOTZ2NEC1NC=>
CWR22RV1 M4WxfmNmdGxiVnnhZoltcXS7IFHzd4F6 MnvPNVAh|ryP NGPOTXQzPCCq NWrtfoZUcW6lcnXhd4V{KHOnboPpeIl3cXS7IH;mJIh2dWGwIFPXVlIzWlZzIHPlcIx{KHSxIILh[IlifGmxbh?= NUjXPG12OjF2OU[yO|M>
CWR22RV1 M3fwNmFxd3C2b4Ppd{BCe3O|YYm= M3;5WFExKM7:TR?= NELhWoszPCCq Mm\T[Y5p[W6lZYOgdoFlcWG2aX;uJIlv\HWlZXSgZZBweHSxc3nz M4q5V|IyPDl4Mkez
CWR22RV1 NXLNPFg1TnWwY4Tpc44hSXO|YYm= MVi1JO69VQ>? MX:yOEBp NE[5fXJz\WS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Ric3nncolncWOjboTsfS=> MV[yNVQ6PjJ5Mx?=
HepG2  M{PxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\VTYM2NzFyL{KwM|QxKM7:TR?= Mk\iNlQwPDhxN{KgbC=> MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Ml:yNlA5PDJ2MkW=
Bel-7402 NGHKV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m1TFUwOTBxMkCvOFAh|ryP M{jOXFI1NzR6L{eyJIg> MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUDnXWdPOjB6NEK0NlU>
HepG2  M2[4[2Z2dmO2aX;uJGF{e2G7 M4DpTlUwOTBxMkCg{txO M37qflI1KGh? NWW5[HluemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl NXnkR3p4OjB6NEK0NlU>
Bel-7402 Mof1SpVv[3Srb36gRZN{[Xl? MknDOU8yOC9{MDFOwG0> Moi4NlQhcA>? MoL1doV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn M1K5Z|IxQDR{NEK1
HepG2  NFz6cGFCeG:ydH;zbZMhSXO|c3H5 M1PCN|UwOTBxMkCg{txO NHnYbFQzPC92ODDo MXLpcoR2[2W|IHHwc5B1d3OrczDheEB1cGVibH;u[{11cW2nIHX4dI9{fXKn NFvlSGYzODh2MkSyOS=>
Bel-7402 NVfkcGY{SXCxcITvd4l{KEG|c4PhfS=> M3\EblUwOTBxMkCg{txO Mm\VNlQwPDhiaB?= M3nwc4lv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= M1\hTVIxQDR{NEK1
OAW-42 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjKNE01OCEQvF2= MoLSO|LDqGh? MoPnTWM2OH5zMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{LLZ|IxPDB3Mkm2
PA-1  NGG5fo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOwMVQxKM7:TR?= MVq3NuKhcA>? M{\wS2lEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NV\xWohROjB2MEWyPVY>
SKOV3  NYnkN2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6wMVQxKM7:TR?= M3f3[VczyqCq MlfiTWM2OH5|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Mn;XNlA1ODV{OU[=
A2780 NXXUcJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiwMVIxKM7:TR?= MWK0PE84OiCq Mk\1TWM2OMLiPdMgN:Kh|ryv M{Gw[VIxPDB3Mkm2
A2780cis  NUXzOJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHS[|BpOC1{MDFOwG0> M3j2VlQ5Nzd{IHi= MkLqTWM2OMLiPdMgOuKh|ryv M3zEclIxPDB3Mkm2
SKW6.4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDQNk0yOMLizszN M1HuOFQ5yqCq MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnjINlAyOzB7NkC=
MAVER NH\ifXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrwOG93Oi1zMNMg{txO M2XpZ|Q5yqCq NWjCOWZTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2j2dFIxOTNyOU[w
BJAB M2XxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7vNpUzNTFywrFOwG0> MkDuOFjDqGh? MljYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NG\kVIkzODF|MEm2NC=>
OCI MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvMNk0yOMLizszN M{HEVFQ5yqCq NVPvWGtWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MW[yNFE{ODl4MB?=
MOLM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17JU|IuOTEEoN88US=> MX20POKhcA>? MlTSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MYWyNFE{ODl4MB?=
HL-60 M37GeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSyMVExyqEQvF2= M3zHeFQ5yqCq NIjjVVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1LJNlIxOTNyOU[w
SKW6.4 NF;HNHlCeG:ydH;zbZMhSXO|c3H5 MlrVNVDDqM7:TR?= M{\PSFI1NzR6IHi= NVnxfYVpcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> Mnu5NlAyOzB7NkC=
MAVER M2jGO2Fxd3C2b4Ppd{BCe3O|YYm= NH\Ze|UyOMLizszN NFnCOlAzPC92ODDo NWHxT3l5cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NGHMNWEzODF|MEm2NC=>
BJAB M2GwR2Fxd3C2b4Ppd{BCe3O|YYm= M33H[FExyqEQvF2= M2rFPFI1NzR6IHi= MkHGbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MWqyNFE{ODl4MB?=
OCI MV7BdI9xfG:|aYOgRZN{e2G7 MonZNVDDqM7:TR?= M1XMVVI1NzR6IHi= M{jsb4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MVSyNFE{ODl4MB?=
MOLM NFLPO2FCeG:ydH;zbZMhSXO|c3H5 MX[xNOKh|ryP MmPxNlQwPDhiaB?= NEDwUHVqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NF3MZ2szODF|MEm2NC=>
HL-60 NWXRZYFLSXCxcITvd4l{KEG|c4PhfS=> NVfGfFc6OTEEoN88US=> MonuNlQwPDhiaB?= MWjpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 MkT5NlAyOzB7NkC=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Unknown status Brain Tumor Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT02238496 Unknown status Brain Tumor Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Completed Cancer AEterna Zentaris January 24 2012 Phase 1
NCT01224730 Completed Cancer AEterna Zentaris January 24 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products4

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID